Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 20 de 215
Filtrar
1.
BMC Cancer ; 21(1): 463, 2021 04 26.
Artículo en Inglés | MEDLINE | ID: mdl-33902516

RESUMEN

BACKGROUND: Over than one third (28-58%) of pregnancy-associated breast cancer (PABC) cases are characterized by positive epidermal growth factor receptor 2-positive (HER2) expression. Trastuzumab anti-HER2 monoclonal antibody is still the benchmark treatment of HER2-positive breast tumors. However, FDA has categorized Trastuzumab as a category D drug for pregnant patients with breast cancer. This systemic review aims to synthesize all currently available data of trastuzumab administration during pregnancy and provide an updated view of the effect of trastuzumab on fetal and maternal outcome. METHODS: Eligible articles were identified by a search of MEDLINE bibliographic database and ClinicalTrials.gov for the period up to 01/09/2020; The algorithm consisted of a predefined combination of the words "breast", "cancer", "trastuzumab" and "pregnancy". This study was performed in accordance with the PRISMA guidelines. RESULTS: A total of 28 eligible studies were identified (30 patients, 32 fetuses). In more than half of cases, trastuzumab was administered in the metastatic setting. The mean duration of trastuzumab administration during gestation was 15.7 weeks (SD: 10.8; median: 17.5; range: 1-32). Oligohydramnios or anhydramnios was the most common (58.1%) adverse event reported in all cases. There was a statistically significant decrease in oligohydramnios/anhydramnios incidence in patients receiving trastuzumab only during the first trimester (P = 0.026, Fisher's exact test). In 43.3% of cases a completely healthy neonate was born. 41.7% of fetuses exposed to trastuzumab during the second and/or third trimester were born completely healthy versus 75.0% of fetuses exposed exclusively in the first trimester. All mothers were alive at a median follow-up of 47.0 months (ranging between 9 and 100 months). Of note, there were three cases (10%) of cardiotoxicity and decreased ejection fraction during pregnancy. CONCLUSIONS: Overall, treatment with trastuzumab should be postponed until after delivery, otherwise pregnancy should be closely monitored.


Asunto(s)
Antineoplásicos Inmunológicos/administración & dosificación , Neoplasias de la Mama/tratamiento farmacológico , Complicaciones Neoplásicas del Embarazo/tratamiento farmacológico , Trastuzumab/administración & dosificación , Adulto , Líquido Amniótico/efectos de los fármacos , Antineoplásicos Inmunológicos/efectos adversos , Antineoplásicos Inmunológicos/farmacología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/química , Cardiotoxicidad/etiología , Femenino , Feto/efectos de los fármacos , Humanos , Persona de Mediana Edad , Oligohidramnios/inducido químicamente , Oligohidramnios/epidemiología , Embarazo , Trimestres del Embarazo , Receptor ErbB-2 , Factores de Tiempo , Trastuzumab/efectos adversos , Trastuzumab/farmacología , Adulto Joven
2.
J Cell Mol Med ; 24(7): 4212-4222, 2020 04.
Artículo en Inglés | MEDLINE | ID: mdl-32119193

RESUMEN

MSCs are kind of cultured cells that reside in different tissues as inducers or regulators of physiological and pathological processes. Here, we derived MSCs from amniotic fluid and compared their differentiation ability and immunosuppression effect on PHA-activated PBMC with those of MSCs isolated from umbilical cords. Amniotic fluid MSCs were isolated and cultured on commercial AFC medium and classic MSC medium, and the number and size of colonies were used to evaluate differences in primary and passaged culture. Rate of proliferation, population doubling time, cell morphology, cell surface markers and mRNA expression were measured in subcultured cells. Furthermore, a comparative study was performed with umbilical cord MSCs to assess the ability of differentiation and immunosuppressive effect of PHA-stimulated PBMCs. Amniotic fluid MSCs were isolated and expanded by three methods, and exhibited nearly all the characteristics of umbilical cord MSCs. Compared with umbilical cord MSCs, amniotic fluid MSCs had an enhanced osteogenic and chrondrogenic differentiation capability, and stronger immunosuppression effect of inhibition of PHA-activated PBMC division. Culture with commercial AFCs medium yielded the highest percentage of CD105 expression and showed some advantages in primary cell isolation, cell source-specific marker retention and cell proliferation. We demonstrated that amniotic fluid MSCs exhibited some advantages over umbilical cord MSCs, and different culture media caused cell proliferation, cell surface marker and cell morphology change, but were not associated with varying differentiation capability and immune effects.


Asunto(s)
Líquido Amniótico/citología , Diferenciación Celular/genética , Endoglina/genética , Osteogénesis/genética , Líquido Amniótico/efectos de los fármacos , Diferenciación Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Separación Celular/métodos , Células Cultivadas , Medios de Cultivo/farmacología , Regulación del Desarrollo de la Expresión Génica/efectos de los fármacos , Humanos , Leucocitos Mononucleares/citología , Leucocitos Mononucleares/efectos de los fármacos , Células Madre Mesenquimatosas/citología , Células Madre Mesenquimatosas/efectos de los fármacos , Osteogénesis/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Cordón Umbilical/citología , Cordón Umbilical/efectos de los fármacos
3.
Mol Hum Reprod ; 26(9): 712-726, 2020 09 01.
Artículo en Inglés | MEDLINE | ID: mdl-32647859

RESUMEN

Sterile intra-amniotic inflammation is a clinical condition frequently observed in women with preterm labor and birth, the leading cause of neonatal morbidity and mortality worldwide. Growing evidence suggests that alarmins found in amniotic fluid, such as interleukin (IL)-1α, are central initiators of sterile intra-amniotic inflammation. However, the causal link between elevated intra-amniotic concentrations of IL-1α and preterm birth has yet to be established. Herein, using an animal model of ultrasound-guided intra-amniotic injection of IL-1α, we show that elevated concentrations of IL-1α cause preterm birth and neonatal mortality. Additionally, using immunoblotting techniques and a specific immunoassay, we report that the intra-amniotic administration of IL-1α induces activation of the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome in the fetal membranes, but not in the decidua, as evidenced by a concomitant increase in the protein levels of NLRP3, active caspase-1, and IL-1ß. Lastly, using Nlrp3-/- mice, we demonstrate that the deficiency of this inflammasome sensor molecule reduces the rates of preterm birth and neonatal mortality caused by the intra-amniotic injection of IL-1α. Collectively, these results demonstrate a causal link between elevated IL-1α concentrations in the amniotic cavity and preterm birth as well as adverse neonatal outcomes, a pathological process that is mediated by the NLRP3 inflammasome. These findings shed light on the mechanisms underlying sterile intra-amniotic inflammation and provide further evidence that this clinical condition can potentially be treated by targeting the NLRP3 inflammasome.


Asunto(s)
Inflamasomas/fisiología , Interleucina-1alfa/fisiología , Nacimiento Prematuro/metabolismo , Alarminas/fisiología , Líquido Amniótico/efectos de los fármacos , Líquido Amniótico/metabolismo , Animales , Animales Recién Nacidos , Femenino , Inflamasomas/efectos de los fármacos , Inflamasomas/metabolismo , Interleucina-1alfa/administración & dosificación , Interleucina-1alfa/farmacología , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Transgénicos , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Embarazo , Nacimiento Prematuro/inducido químicamente , Nacimiento Prematuro/genética
4.
Prenat Diagn ; 40(9): 1178-1184, 2020 08.
Artículo en Inglés | MEDLINE | ID: mdl-32441341

RESUMEN

Antimicrobial prophylaxis during surgery aims to prevent post-operative site infections. For fetal surgery, this includes the fetal and amniotic compartments. Both are deep compartments as drug equilibrium with maternal blood is achieved relatively late. Despite prophylaxis, chorio-amnionitis or endometritis following ex utero intrapartum treatment or fetoscopy occur in 4.13% and 1.45% respectively of the interventions. This review summarizes the observations on two commonly administered antimicrobials (cefazolin, clindamycin) for surgical prophylaxis during pregnancy, with emphasis on the deep compartments. For both compounds, antimicrobial exposure is on target when we consider the maternal and fetal plasma compartment. In contrast, amniotic fluid concentrations-time profiles display a delayed and much more blunted pattern, behaving as deep compartment. For cefazolin, there are data that document further dilution in the setting of polyhydramnios. Along this deep compartment concept, there is some accumulation during repeated administration, modeled for cefazolin and observed for clindamycin. The relative underexposure to antimicrobials in amniotic fluid may be reflected in the pattern of maternal-fetal complications after fetal surgery, and suggest that antimicrobial prophylaxis practices for fetal surgery should be reconsidered. Further studies should be designed by a multidisciplinary team (fetal surgeons, clinical pharmacologists and microbiologists) to facilitate efficient evaluation of antimicrobial prophylaxis.


Asunto(s)
Antibacterianos/farmacocinética , Fetoscopía , Embarazo/metabolismo , Líquido Amniótico/efectos de los fármacos , Líquido Amniótico/metabolismo , Antibacterianos/sangre , Antibacterianos/uso terapéutico , Profilaxis Antibiótica/métodos , Cefazolina/sangre , Cefazolina/farmacocinética , Cefazolina/uso terapéutico , Clindamicina/sangre , Clindamicina/farmacocinética , Clindamicina/uso terapéutico , Femenino , Fetoscopía/métodos , Feto/irrigación sanguínea , Feto/efectos de los fármacos , Feto/metabolismo , Humanos , Recién Nacido , Masculino , Circulación Placentaria/efectos de los fármacos , Embarazo/sangre
5.
Reproduction ; 158(4): 369-376, 2019 10.
Artículo en Inglés | MEDLINE | ID: mdl-31454783

RESUMEN

The amniotic fluid provides mechanical protection and immune defense against pathogens to the fetus. Indeed, components of the innate and adaptive immunity, including B cells, have been described in the amniotic fluid. However, limited information concerning phenotype and functionality of amniotic fluid B cells is available. Hence, we aimed to perform a full phenotypical and functional characterization of amniotic fluid B cells in normal pregnancy and in a mouse model of preterm birth. Phenotypic analysis depicted the presence of two populations of amniotic fluid B cells: an immature population, resembling B1 progenitor cells and a more mature population. Further isolation and in vitro co-culture with a bone marrow stroma cell line demonstrated the capacity of the immature B cells to mature. This was further supported by spontaneous production of IgM, a feature of the B1 B cell sub-population. An additional in vitro stimulation with lipopolysaccharide induced the activation of amniotic fluid B cells as well as the production of pro and anti-inflammatory cytokines. Furthermore, amniotic fluid B cells were expanded in the acute phase of LPS-induced preterm birth. Overall our data add new insight not only on the phenotype and developmental stage of the amniotic fluid B1 B cells but especially on their functionality. This provides important information for a better understanding of their role within the amniotic fluid as immunological protective barrier, especially with regard to intraamniotic infection and preterm birth.


Asunto(s)
Líquido Amniótico/inmunología , Linfocitos B/inmunología , Citocinas/metabolismo , Inflamación/fisiopatología , Nacimiento Prematuro/inmunología , Líquido Amniótico/efectos de los fármacos , Líquido Amniótico/metabolismo , Animales , Linfocitos B/citología , Linfocitos B/efectos de los fármacos , Femenino , Inmunoglobulina M/metabolismo , Lipopolisacáridos/farmacología , Masculino , Ratones , Ratones Endogámicos BALB C , Ratones Endogámicos C57BL , Embarazo , Nacimiento Prematuro/metabolismo , Nacimiento Prematuro/patología
6.
Amino Acids ; 51(5): 805-811, 2019 May.
Artículo en Inglés | MEDLINE | ID: mdl-30879150

RESUMEN

We recently reported that dietary supplementation with L-proline (proline) during gestation improved embryonic survival in C57BL/6J mice. The objective of the present study was to test the hypothesis that the effect of maternal proline supplementation on embryonic survival can be carried forward to the first generation female offspring. In the F0 generation, pregnant dams were fed a purified diet supplemented with 0 (control) or 5 g proline/kg diet. The F1 female adult offsprings were bred to fertile males. Fetal survival at embryonic day (E)12.5 and reproductive outcomes at term birth were recorded. The concentrations of amino acids, ammonia, and urea in plasma and amniotic fluid, as well as concentrations of polyamines in placental tissues and amniotic fluid at E12.5 were determined. Results showed that the F1 generation female offspring from proline-supplemented dams had higher (P < 0.05) concentrations of glutamate and taurine in plasma; of putrescine and spermidine in placental tissues; and of glycine, taurine, and spermidine in amniotic fluid at E12.5, as compared with F1 generation female offsprings from dams without proline supplementation. Concentration of proline in the plasma of offspring mice from proline-supplemented dams were lower (P < 0.05), as compared with the control group. No differences in fetal survival, reproductive outcomes, or concentrations of ammonia and urea in plasma and amniotic fluid were observed between the two groups of F1 female offspring. Collectively, our results indicate that the benefits of maternal proline supplementation during gestation on improving embryonic survival and fetal growth in F0 females are not transmitted to their F1 generation females.


Asunto(s)
Aminoácidos/metabolismo , Suplementos Dietéticos , Desarrollo Fetal/efectos de los fármacos , Placenta/metabolismo , Poliaminas/metabolismo , Efectos Tardíos de la Exposición Prenatal/metabolismo , Prolina/administración & dosificación , Líquido Amniótico/efectos de los fármacos , Líquido Amniótico/metabolismo , Animales , Femenino , Masculino , Ratones , Ratones Endogámicos C57BL , Placenta/efectos de los fármacos , Embarazo , Efectos Tardíos de la Exposición Prenatal/tratamiento farmacológico
7.
J Neuroinflammation ; 15(1): 113, 2018 Apr 19.
Artículo en Inglés | MEDLINE | ID: mdl-29673373

RESUMEN

BACKGROUND: Antenatal infection (i.e., chorioamnionitis) is an important risk factor for adverse neurodevelopmental outcomes after preterm birth. Destructive and developmental disturbances of the white matter are hallmarks of preterm brain injury. Understanding the temporal effects of antenatal infection in relation to the onset of neurological injury is crucial for the development of neurotherapeutics for preterm infants. However, these dynamics remain unstudied. METHODS: Time-mated ewes were intra-amniotically injected with lipopolysaccharide at 5, 12, or 24 h or 2, 4, 8, or 15 days before preterm delivery at 125 days gestational age (term ~ 150 days). Post mortem analyses for peripheral immune activation, neuroinflammation, and white matter/neuronal injury were performed. Moreover, considering the neuroprotective potential of erythropoietin (EPO) for perinatal brain injury, we evaluated (phosphorylated) EPO receptor (pEPOR) expression in the fetal brain following LPS exposure. RESULTS: Intra-amniotic exposure to this single bolus of LPS resulted in a biphasic systemic IL-6 and IL-8 response. In the developing brain, intra-amniotic LPS exposure induces a persistent microgliosis (IBA-1 immunoreactivity) but a shorter-lived increase in the pro-inflammatory marker COX-2. Cell death (caspase-3 immunoreactivity) was only observed when LPS exposure was greater than 8 days in the white matter, and there was a reduction in the number of (pre) oligodendrocytes (Olig2- and PDGFRα-positive cells) within the white matter at 15 days post LPS exposure only. pEPOR expression displayed a striking biphasic regulation following LPS exposure which may help explain contradicting results among clinical trials that tested EPO for the prevention of preterm brain injury. CONCLUSION: We provide increased understanding of the spatiotemporal pathophysiological changes in the preterm brain following intra-amniotic inflammation which may aid development of new interventions or implement interventions more effectively to prevent perinatal brain damage.


Asunto(s)
Lesiones Encefálicas/etiología , Corioamnionitis/etiología , Inflamación/etiología , Nacimiento Prematuro/fisiopatología , Efectos Tardíos de la Exposición Prenatal/fisiopatología , Líquido Amniótico/efectos de los fármacos , Animales , Femenino , Feto , Edad Gestacional , Lipopolisacáridos/toxicidad , Embarazo , Nacimiento Prematuro/inducido químicamente , Ovinos , Factores de Tiempo
8.
Dev Neurosci ; 39(6): 472-486, 2017.
Artículo en Inglés | MEDLINE | ID: mdl-28848098

RESUMEN

Chorioamnionitis is associated with adverse neurodevelopmental outcomes in preterm infants. Ureaplasma spp. are the microorganisms most frequently isolated from the amniotic fluid of women diagnosed with chorioamnionitis. However, controversy remains concerning the role of Ureaplasma spp. in the pathogenesis of neonatal brain injury. We hypothesize that reexposure to an inflammatory trigger during the perinatal period might be responsible for the variation in brain outcomes of preterms following Ureaplasma-driven chorioamnionitis. To investigate these clinical scenarios, we performed a detailed multimodal study in which ovine neurodevelopmental outcomes were assessed following chronic intra-amniotic Ureaplasma parvum (UP) infection either alone or combined with subsequent lipopolysaccharide (LPS) exposure. We show that chronic intra-amniotic UP exposure during the second trimester provoked a decrease in astrocytes, increased oligodendrocyte numbers, and elevated 5-methylcytosine levels. In contrast, short-term LPS exposure before preterm birth induced increased microglial activation, myelin loss, elevation of 5-hydroxymethylcytosine levels, and lipid profile changes. These LPS-induced changes were prevented by chronic preexposure to UP (preconditioning). These data indicate that chronic UP exposure has dual effects on preterm brain development in utero. On the one hand, prolonged UP exposure causes detrimental cerebral changes that may predispose to adverse postnatal clinical outcomes. On the other, chronic intra-amniotic UP exposure preconditions the brain against a second inflammatory hit. This study demonstrates that microbial interactions and the timing and duration of the inflammatory insults determine the effects on the fetal brain. Therefore, this study helps to understand the complex and diverse postnatal neurological outcomes following UP driven chorioamnionitis.


Asunto(s)
Encéfalo/embriología , Corioamnionitis/patología , Desarrollo Fetal/efectos de los fármacos , Infecciones por Ureaplasma , Ureaplasma , Líquido Amniótico/efectos de los fármacos , Animales , Encéfalo/efectos de los fármacos , Femenino , Lipopolisacáridos/farmacología , Embarazo , Ovinos
9.
Br J Clin Pharmacol ; 83(7): 1571-1579, 2017 07.
Artículo en Inglés | MEDLINE | ID: mdl-28042936

RESUMEN

AIMS: Diabetes mellitus can inhibit cytochrome P450 3A4, an enzyme responsible for the metabolism of nifedipine, used for the treatment of hypertension in pregnant women. We aimed to assess the effect of type 2 diabetes mellitus (T2DM) on the pharmacokinetics, placental transfer and distribution of nifedipine in amniotic fluid in hypertensive pregnant women. METHODS: The study was conducted in 12 hypertensive pregnant women [control group (CG)] and 10 hypertensive pregnant women with T2DM taking slow-release nifedipine (20 mg, 12/12 h). On the 34th week of gestation, serial blood samples were collected (0-12 h) after administration of the medication. At delivery, samples of maternal and fetal blood and amniotic fluid were collected for determination of nifedipine distribution in these compartments. RESULTS: The median pharmacokinetic parameters of CG were: peak plasma concentration (Cmax ) 26.41 ng ml-1 , time to reach Cmax (tmax ) 1.79 h, area under the plasma concentration vs. time curve from 0-12 h (AUC0-12 ) 235.99 ng.h ml-1 , half-life (t½) 4.34 h, volume of distribution divided by bioavailability (Vd/F) 560.96 l, and ClT /F 84.77 l h-1 . The parameters for T2DM group were: Cmax 23.52 ng ml-1 , tmax 1.48 h, AUC0-12 202.23 ng.h ml-1 , t½ 5.00 h, Vd/F 609.40 l, and apparent total clearance (ClT /F) 98.94 l h-1 . The ratios of plasma concentrations of nifedipine in the umbilical vein, intervillous space and amniotic fluid to those in the maternal vein for CG and T2DM were 0.53 and 0.44, 0.78 and 0.87, respectively, with an amniotic fluid/maternal plasma ratio of 0.05 for both groups. The ratios of plasma concentrations in the umbilical artery to those in the umbilical vein were 0.82 for CG and 0.88 for T2DM. CONCLUSIONS: There was no influence of T2DM on the pharmacokinetics or placental transfer of nifedipine in hypertensive women with controlled diabetes.


Asunto(s)
Bloqueadores de los Canales de Calcio/farmacocinética , Citocromo P-450 CYP3A/metabolismo , Diabetes Mellitus Tipo 2/metabolismo , Hipertensión/tratamiento farmacológico , Nifedipino/farmacocinética , Complicaciones Cardiovasculares del Embarazo/tratamiento farmacológico , Adulto , Líquido Amniótico/química , Líquido Amniótico/efectos de los fármacos , Disponibilidad Biológica , Bloqueadores de los Canales de Calcio/uso terapéutico , Estudios de Casos y Controles , Preparaciones de Acción Retardada/farmacocinética , Preparaciones de Acción Retardada/uso terapéutico , Femenino , Semivida , Humanos , Nifedipino/uso terapéutico , Placenta/metabolismo , Embarazo
10.
Reprod Fertil Dev ; 29(3): 565-574, 2017 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26434602

RESUMEN

The modification of pre- and postnatal development conferred by immunogenic stimulation of mothers provides a population-level adaptation mechanism for non-genetic transfer of maternal experiences to progeny. However little is known about the transmission of paternal immune experiences to offspring. Here, we show that immune priming of males 3-9 days before mating affects the growth and humoral environment of developing embryos of outbred (ICR) and inbred (C57BL and BALB/c) mice. Antigenic stimulation of fathers caused a significant increase in embryonic bodyweight as measured on Day 16 of pregnancy and altered other gestation parameters, such as feto-placental ratio. Pregnant females mated with immunised males were also characterised by changes in humoral conditions as shown by measurements of blood and amniotic progesterone, testosterone and granulocyte-macrophage colony-stimulating factor (GM-CSF) cytokine concentrations. These results emphasise the role of paternal effects of immune priming on the in utero environment and fetal growth.


Asunto(s)
Adyuvantes Inmunológicos/administración & dosificación , Peso Corporal/inmunología , Desarrollo Embrionario/inmunología , Hemocianinas/administración & dosificación , Reproducción/inmunología , Líquido Amniótico/efectos de los fármacos , Líquido Amniótico/metabolismo , Animales , Peso Corporal/efectos de los fármacos , Desarrollo Embrionario/efectos de los fármacos , Femenino , Factor Estimulante de Colonias de Granulocitos y Macrófagos/metabolismo , Inmunización , Masculino , Ratones , Embarazo , Progesterona/metabolismo , Reproducción/efectos de los fármacos , Testosterona/metabolismo
11.
Environ Toxicol ; 32(4): 1412-1425, 2017 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27539004

RESUMEN

PM2.5 travels along the respiratory tract and enters systemic blood circulation. Studies have shown that PM2.5 increases the incidence of various diseases not only in adults but also in newborn infants. It causes chronic inflammation in pregnant women and retards fetal development. In this study, pregnant rats were exposed to PM2.5 for extended periods of time and it was found that PM2.5 exposure increased immune cells in mother rats. In addition, cytokines and free radicals rapidly accumulated in the amniotic fluid and indirectly affected the fetuses. The authors collected cerebral cortex and hippocampus samples at E18 and analyzed changes of miRNA levels. Expression levels of cortical miR-6315, miR-3588, and miR-466b-5p were upregulated, and positively correlated with the genes Pkn2 (astrocyte migration), Gorab (neuritogenesis), and Mobp (allergic encephalomyelitis). In contrast, PM2.5 decreased expression of miR-338-5p and let-7e-5p, both related to mental development. Further, PM2.5 exposure increased miR-3560 and let-7b-5p in the hippocampus, two proteins that regulate genes Oxct1 and Lin28b that control ketogenesis and glycosylation, and neural cell differentiation, respectively. miR-99b-5p, miR-92b-5p, and miR-99a-5p were decreased, leading to reduced expression of Kbtbd8 and Adam11 which reduced cell mitosis, migration, and differentiation, and inhibited learning abilities and motor coordination of the fetus. © 2016 Wiley Periodicals, Inc. Environ Toxicol 32: 1412-1425, 2017.


Asunto(s)
Contaminantes Atmosféricos/toxicidad , Hipocampo/efectos de los fármacos , Exposición Materna , Material Particulado/toxicidad , Adulto , Líquido Amniótico/efectos de los fármacos , Líquido Amniótico/metabolismo , Animales , Corteza Cerebral/efectos de los fármacos , Corteza Cerebral/metabolismo , Citocinas/metabolismo , Femenino , Regulación del Desarrollo de la Expresión Génica/efectos de los fármacos , Hipocampo/metabolismo , Humanos , Intercambio Materno-Fetal , MicroARNs/biosíntesis , MicroARNs/genética , Embarazo , Ratas , Ratas Sprague-Dawley , Transcriptoma/efectos de los fármacos
12.
J Appl Toxicol ; 36(9): 1183-93, 2016 09.
Artículo en Inglés | MEDLINE | ID: mdl-26815315

RESUMEN

Cadmium is a well-characterized nephrotoxic agent that is also capable of accumulating and diffusing across the placenta; however, only a few studies have addressed its effects over fetal kidneys and none of them has used a panel of sensitive and specific biomarkers for the detection of kidney injury. The goal of this study was to determine cadmium renal effects in rat fetuses by the quantification of early kidney injury biomarkers. Pregnant Wistar rats were exposed by inhalation to an isotonic saline solution or to CdCl2 solution (DDel =1.48 mg Cd kg(-1) day(-1) ) during gestational days (GD) 8-20. On GD 21, dams were euthanized and samples obtained. Kidney injury biomarkers were quantified in amniotic fluid samples and fetal kidneys were microscopically evaluated to search for histological alterations. Our results showed that cadmium exposure significantly raised albumin, osteopontin, vascular endothelial growth factor and tissue inhibitor of metalloproteinases-1 levels in amniotic fluid, whereas it decreased creatinine. Clusterin, calbindin and IFN-inducible protein 10 did not show any change. Accordingly, histological findings showed tubular damage and precipitations in the renal pelvis. In conclusion, gestational exposure to cadmium induces structural alterations in fetal renal tissue that can be detected by some kidney injury biomarkers in amniotic fluid samples. Copyright © 2016 John Wiley & Sons, Ltd.


Asunto(s)
Biomarcadores/metabolismo , Cadmio/toxicidad , Enfermedades Renales/metabolismo , Riñón/efectos de los fármacos , Líquido Amniótico/efectos de los fármacos , Líquido Amniótico/metabolismo , Animales , Calbindina 1/genética , Calbindina 1/metabolismo , Quimiocina CXCL10/genética , Quimiocina CXCL10/metabolismo , Clusterina/genética , Clusterina/metabolismo , Creatinina/metabolismo , Femenino , Feto/efectos de los fármacos , Feto/metabolismo , Glutatión Transferasa/genética , Glutatión Transferasa/metabolismo , Isoenzimas/genética , Isoenzimas/metabolismo , Riñón/metabolismo , Enfermedades Renales/inducido químicamente , Metaloproteasas/genética , Metaloproteasas/metabolismo , Osteopontina/genética , Osteopontina/metabolismo , Embarazo , Ratas , Ratas Wistar , Factor A de Crecimiento Endotelial Vascular/genética , Factor A de Crecimiento Endotelial Vascular/metabolismo
13.
J Pak Med Assoc ; 66(4): 435-8, 2016 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-27122271

RESUMEN

OBJECTIVE: To investigate the effect of high-dose fluoride on antioxidant enzyme activities of amniotic fluid and fluoride of serum in rats. METHODS: The experimental study was conducted from January 8, 2008, to December 14, 2010, at the Suleyman Demirel University Experimental Animals Laboratory and the Medical Biochemistry Department Research Laboratory, Isparta, Turkey. Impregnated Wistar albino rats were divided into two equal groups. Group I had controls, while Group II rats were exposed to high-dose fluoride. Group I was given drinking water mixed with 0.1 mg/kg/b.w./day of natrium fluoride, while group II was given drinking water mixed with 10 mg/kg/b.w./day of natrium fluoride for 18 days. At the end of 18 days, amniotic fluid and blood samples were collected from control and experimental groups of pregnancy. Superoxide dismutase, glutathione peroxidase, catalase activities and thiobarbituric acid reactive substances as antioxidant enzymes in amniotic fluid and levels of fluoride in serum samples were investigated. RESULTS: There were 14 rats, with 7(50%) in each group. Foetal weight in group II significantly decreased compared to the control group (p< 0.05). Antioxidant enzyme activities in amniotic fluid were significantly higher in group II than group I (p< 0.05) although thiobarbituric acid reactive substances in amniotic fluid and serum fluoride levels were significantly lower in group II than group I (p< 0.05). CONCLUSIONS: Fluoride that created oxidative stress inhibited lipid peroxidation and apparently increased the antioxidant defence system.


Asunto(s)
Líquido Amniótico/efectos de los fármacos , Cariostáticos/farmacología , Catalasa/efectos de los fármacos , Glutatión Peroxidasa/efectos de los fármacos , Peroxidación de Lípido/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Fluoruro de Sodio/farmacología , Superóxido Dismutasa/efectos de los fármacos , Líquido Amniótico/enzimología , Animales , Cariostáticos/administración & dosificación , Catalasa/metabolismo , Femenino , Glutatión Peroxidasa/metabolismo , Embarazo , Ratas , Ratas Wistar , Fluoruro de Sodio/administración & dosificación , Superóxido Dismutasa/metabolismo , Sustancias Reactivas al Ácido Tiobarbitúrico/metabolismo
14.
Cell Physiol Biochem ; 36(1): 259-73, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25967965

RESUMEN

BACKGROUND/AIMS: Mesenchymal stem cells from human amniotic fluid (huAFMSCs) can differentiate into multiple lineages and are not tumorigenic after transplantation, making them good candidates for therapeutic purposes. The aim was to determine the effects of calcitonin on these huAFMSCs during osteogenic differentiation, in terms of the physiological role of calcitonin in bone homeostasis. METHODS: For huAFMSCs cultured under different conditions, we assayed: expression of the calcitonin receptor, using immunolabelling techniques; proliferation and osteogenesis, using colorimetric and enzymatic assays; intracellular Ca(2+) and cAMP levels, using videomicroscopy and spectrophotometry. RESULTS: The calcitonin receptor was expressed in proliferating and osteo-differentiated huAFMSCs. Calcitonin triggered intracellular Ca(2+) increases and cAMP production. Its presence in cell medium also induced dose-dependent inhibitory effects on proliferation and increased osteogenic differentiation of huAFMSCs, as also indicated by enhancement of specific markers and alkaline phosphatase activity. CONCLUSIONS: These data show that huAFMSCs represent a potential osteogenic model to study in-vitro cell responses to calcitonin (and other members of the calcitonin family). This leads the way to the opening of new lines of research that will add new insight both in cell therapies and in the pharmacological use of these molecules.


Asunto(s)
Líquido Amniótico/citología , Calcitonina/farmacología , Células Madre Mesenquimatosas/efectos de los fármacos , Osteogénesis/efectos de los fármacos , Líquido Amniótico/efectos de los fármacos , Líquido Amniótico/metabolismo , Biomarcadores/metabolismo , Calcio/metabolismo , Diferenciación Celular/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Células Cultivadas , AMP Cíclico/metabolismo , Femenino , Humanos , Células Madre Mesenquimatosas/citología , Células Madre Mesenquimatosas/metabolismo , Embarazo , Receptores de Calcitonina/metabolismo
15.
J Anat ; 227(6): 767-80, 2015 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25833670

RESUMEN

Amniotic fluid-derived stem cells (AFSCs) are a unique stem cell source that may have great potential for use in tissue engineering (TE) due to their pluripotentiality. AFSCs have previously shown angiogenic potential and may present an alternative cell source for endothelial-like cells that could be used in range of applications, including the pre-vascularisation of TE constructs and the treatment of ischaemic diseases. This study investigated the ability of these cells to differentiate down an endothelial lineage with the aim of producing an endothelial-like cell suitable for use in pre-vascularisation. As hypoxia and the associated HIF-1 pathway have been implicated in the induction of angiogenesis in a number of biological processes, it was hypothesised that culture in hypoxic conditions could enhance the endothelial differentiation of AFSCs. The cells were cultured in endothelial cell media supplemented with 50 ng mL(-1) of VEGF, maintained in normoxia, intermittent hypoxia or continuous hypoxia and assessed for markers of endothelial differentiation at day 7 and 14. The results demonstrated that AFSCs subjected to these culture conditions display an endothelial gene expression profile and adopted functional endothelial cell characteristics indicative of early endothelial differentiation. Culture in continuous hypoxia enhanced endothelial gene expression but did not enhance functional endothelial cell characteristics. Overall, AFSCs subjected to endothelial stimuli demonstrated a less mature endothelial gene expression profile and phenotype when compared with HUVECs, the endothelial cell control. However, this study is the first time that the positive effect of an extended period of continuous hypoxic culture on endothelial differentiation in AFSCs has been demonstrated.


Asunto(s)
Líquido Amniótico/citología , Diferenciación Celular/fisiología , Células Endoteliales/citología , Células Madre Pluripotentes/citología , Ingeniería de Tejidos/métodos , Líquido Amniótico/efectos de los fármacos , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/genética , Hipoxia de la Célula , Células Cultivadas , Células Endoteliales/metabolismo , Células Endoteliales de la Vena Umbilical Humana/citología , Células Endoteliales de la Vena Umbilical Humana/metabolismo , Humanos , Subunidad alfa del Factor 1 Inducible por Hipoxia/biosíntesis , Células Madre Pluripotentes/metabolismo , Transcriptoma , Factor A de Crecimiento Endotelial Vascular/farmacología
16.
Pediatr Res ; 77(1-1): 29-35, 2015 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-25285474

RESUMEN

BACKGROUND: Intrauterine inflammation activates the fetal immune system and can result in organ injury and postnatal complications in preterm infants. As the spleen is an important site for peripheral immune activation, we asked how the fetal spleen would respond to intrauterine inflammation over time. We hypothesized that intraamniotic lipopolysaccharide (IA LPS) exposure induces acute and persistent changes in the splenic cytokine profile and T-cell composition that may contribute to the sustained fetal inflammatory response after chorioamnionitis. METHODS: Fetal sheep were exposed to IA LPS 5, 12, and 24 h and 2, 4, 8, or 15 d before delivery at 125 d of gestational age (term = 150 d). Splenic cytokine mRNA levels and cleaved caspase-3, CD3, and Foxp3 expression were evaluated. RESULTS: IA LPS increased interleukin (IL)1, IL4, IL5, and IL10 mRNA by twofold 24 h after injection. Interferon gamma increased by fivefold, whereas IL23 decreased 15 d post-LPS exposure. Cleaved caspase-3-positive cells increased 2 and 8 d after LPS exposure. CD3 immunoreactivity increased within 5 h with increased Foxp3-positive cells at 12 h. CONCLUSION: Intrauterine inflammation induced a rapid and sustained splenic immune response with persistent changes in the cytokine profile. This altered immune status may drive sustained inflammation and injury in other fetal organs.


Asunto(s)
Líquido Amniótico/metabolismo , Lipopolisacáridos/química , Bazo/inmunología , Líquido Amniótico/efectos de los fármacos , Animales , Apoptosis , Complejo CD3/metabolismo , Caspasa 3/metabolismo , Corioamnionitis/fisiopatología , Citocinas/metabolismo , Femenino , Feto/metabolismo , Edad Gestacional , Sistema Inmunológico , Inflamación , Interleucina-23/metabolismo , Modelos Animales , Embarazo , Preñez , ARN Mensajero/metabolismo , Ovinos , Bazo/metabolismo
17.
Antimicrob Agents Chemother ; 58(9): 5413-20, 2014 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-24982089

RESUMEN

Intrauterine infection with Ureaplasma spp. is strongly associated with preterm birth and adverse neonatal outcomes. We assessed whether combined intraamniotic (IA) and maternal intravenous (IV) treatment with one of two candidate antibiotics, azithromycin (AZ) or solithromycin (SOLI), would eradicate intrauterine Ureaplasma parvum infection in a sheep model of pregnancy. Sheep with singleton pregnancies received an IA injection of U. parvum serovar 3 at 85 days of gestational age (GA). At 120 days of GA, animals (n=5 to 8/group) received one of the following treatments: (i) maternal IV SOLI with a single IA injection of vehicle (IV SOLI only); (ii) maternal IV SOLI with a single IA injection of SOLI (IV+IA SOLI); (iii) maternal IV AZ and a single IA injection of vehicle (IV AZ only); (iv) maternal IV AZ and a single IA injection of AZ (IV+IA AZ); or (v) maternal IV and single IA injection of vehicle (control). Lambs were surgically delivered at 125 days of GA. Treatment efficacies were assessed by U. parvum culture, quantitative PCR, enzyme-linked immunosorbent assay, and histopathology. Amniotic fluid (AF) from all control animals contained culturable U. parvum. AF, lung, and chorioamnion from all AZ- or SOLI-treated animals (IV only or IV plus IA) were negative for culturable U. parvum. Relative to the results for the control, the levels of expression of interleukin 1ß (IL-1ß), IL-6, IL-8, and monocyte chemoattractant protein 2 (MCP-2) in fetal skin were significantly decreased in the IV SOLI-only group, the MCP-1 protein concentration in the amniotic fluid was significantly increased in the IV+IA SOLI group, and there was no significant difference in the histological inflammation scoring of lung or chorioamnion among the five groups. In the present study, treatment with either AZ or SOLI (IV only or IV+IA) effectively eradicated macrolide-sensitive U. parvum from the AF. There was no discernible difference in antibiotic therapy efficacy between IV-only and IV+IA treatment regimens relative to the results for the control.


Asunto(s)
Líquido Amniótico/efectos de los fármacos , Líquido Amniótico/microbiología , Azitromicina/farmacología , Macrólidos/farmacología , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , Triazoles/farmacología , Infecciones por Ureaplasma/tratamiento farmacológico , Ureaplasma/efectos de los fármacos , Administración Intravenosa/métodos , Animales , Antibacterianos/farmacología , Quimiocina CCL2/metabolismo , Quimiocina CCL8/metabolismo , Femenino , Feto/efectos de los fármacos , Interleucinas/metabolismo , Pulmón/efectos de los fármacos , Pulmón/metabolismo , Neumonía/metabolismo , Embarazo , Complicaciones Infecciosas del Embarazo/metabolismo , Complicaciones Infecciosas del Embarazo/microbiología , Ovinos , Infecciones por Ureaplasma/metabolismo
18.
Acta Obstet Gynecol Scand ; 93(1): 80-5, 2014 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-24102442

RESUMEN

OBJECTIVE: To assess whether the frequency of adverse neonatal outcome at delivery is related to the level of lactate in amniotic fluid and to the use of oxytocin. DESIGN: Prospective observational study. SETTING: Soder Hospital, Stockholm, Sweden. POPULATION: Seventy-four women in active labor with a gestational age ≥36 weeks and mixed parity. METHODS: Levels of lactate in amniotic fluid were analyzed bedside from an intrauterine catheter every 30 min during labor. Deliveries were divided into groups with and without oxytocin. MAIN OUTCOME MEASURES: The frequency of adverse neonatal outcome at delivery. RESULT: Of the deliveries 13.5% (10/74) concluded with an adverse neonatal outcome. The levels of lactate in amniotic fluid increased during labor, more so in deliveries where oxytocin was used. In the group with an adverse neonatal outcome, the level of lactate in amniotic fluid was significantly higher in the final sample before delivery (p = 0.04). In 18 deliveries, stimulation with oxytocin was temporarily halted for at least 30 min due to overly stimulated labor contractions. A decreasing level of lactate in amniotic fluid was shown within a median 5%/30 min. In the group where the administration of oxytocin was halted, there was no adverse neonatal outcome. CONCLUSION: The frequency of adverse neonatal outcome was associated with the level of lactate in amniotic fluid and with the use of oxytocin. The level of lactate in amniotic fluid may be an additional valuable tool when oxytocin is administered during labor.


Asunto(s)
Líquido Amniótico/química , Trabajo de Parto , Ácido Láctico/análisis , Oxitocina/administración & dosificación , Adulto , Líquido Amniótico/efectos de los fármacos , Puntaje de Apgar , Femenino , Humanos , Recién Nacido , Embarazo , Resultado del Embarazo , Estudios Prospectivos
19.
Gynecol Obstet Invest ; 77(4): 245-9, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24642648

RESUMEN

AIM: To verify the eventual efficacy of lactoferrin (LF), an iron-binding glycoprotein, to decrease the amniotic concentration of interleukin-6 (IL-6). METHODS: We prospectively enrolled 60 Caucasian patients at the 16th week of their singleton physiological gestation. A vaginal compound containing 300 mg of LF was administered randomly 4 or 12 h prior to amniocentesis, as to obtain 3 groups: A, 20 untreated patients; B, 20 treated 4 h before amniocentesis; C, 20 treated 12 h before amniocentesis. RESULTS: A normal karyotype was registered in all cases. The comparison of the distribution of IL-6 among the 3 groups showed a highly significant difference (p = 0.001). The difference between mean values of group B and both groups C and A was shown to be highly significant (p = 0.006 and p = 0.03, respectively). In contrast, there was no significant difference between mean values of groups A and C. CONCLUSION: Vaginal LF administration decreases amniotic IL-6 concentration. We therefore suggest that the glycoprotein may exert a protective role against ominous pregnancy complications linked to an increased level of the cytokine, such as abortion secondary to amniocentesis.


Asunto(s)
Amniocentesis , Líquido Amniótico/efectos de los fármacos , Antiinfecciosos/farmacología , Antiinflamatorios/farmacología , Interleucina-6/metabolismo , Lactoferrina/farmacología , Embarazo/efectos de los fármacos , Administración Intravaginal , Adulto , Líquido Amniótico/metabolismo , Antiinfecciosos/administración & dosificación , Antiinflamatorios/administración & dosificación , Biomarcadores/metabolismo , Esquema de Medicación , Femenino , Humanos , Lactoferrina/administración & dosificación , Evaluación del Resultado de la Atención al Paciente , Embarazo/metabolismo , Segundo Trimestre del Embarazo
20.
Curr Pharm Des ; 30(25): 1995-2006, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38867535

RESUMEN

BACKGROUND: Smoking during pregnancy has been linked to adverse health outcomes in offspring, but the underlying mechanisms are not fully understood. To date, the effect of maternal smoking has been tested in primary tissues and animal models, but the scarcity of human tissues limits experimental studies. Evidence regarding smoking-related molecular alteration and gene expression profiles in stem cells is still lacking. METHODS: We developed a cell culture model of human amniotic fluid stem cells (hAFSCs) of nicotine (NIC) exposure to examine the impact of maternal smoking on epigenetic alterations of the fetus. RESULTS: NIC 0.1 µM (equivalent to "light" smoking, i.e., 5 cigarettes/day) did not significantly affect cell viability; however, significant alterations in DNA methylation and N6-methyladenosine (m6A) RNA methylation in hAFSCs occurred. These epigenetic changes may influence the gene expression and function of hAFSCs. Furthermore, NIC exposure caused time-dependent alterations of the expression of pluripotency genes and cell surface markers, suggesting enhanced cell stemness and impaired differentiation potential. Furthermore, NICtreated cells showed reduced mRNA levels of key adipogenic markers and hypomethylation of the promoter region of the imprinted gene H19 during adipogenic differentiation, potentially suppressing adipo/lipogenesis. Differential expression of 16 miRNAs, with predicted target genes involved in various metabolic pathways and linked to pathological conditions, including cognitive delay and fetal growth retardation, has been detected. CONCLUSION: Our findings highlight multi-level effects of NIC on hAFSCs, including epigenetic modifications, altered gene expression, and impaired cellular differentiation, which may contribute to long-term consequences of smoking in pregnancy and its potential impact on offspring health and development.


Asunto(s)
Líquido Amniótico , Epigénesis Genética , Nicotina , Células Madre , Humanos , Líquido Amniótico/citología , Líquido Amniótico/metabolismo , Líquido Amniótico/efectos de los fármacos , Epigénesis Genética/efectos de los fármacos , Nicotina/farmacología , Células Madre/efectos de los fármacos , Células Madre/metabolismo , Femenino , Células Cultivadas , Embarazo , Diferenciación Celular/efectos de los fármacos , Metilación de ADN/efectos de los fármacos
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda